CRIS Curis Inc.

1.74
-0.03  -2%
Previous Close 1.77
Open 1.78
Price To Book -12.43
Market Cap 57682357
Shares 33,150,780
Volume 92,725
Short Ratio
Av. Daily Volume 728,373

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due mid-2019.
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 data for mesothelioma due 2H 2019.
CA170
Solid Tumors and Lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 1b initial data in DH/DE DLBCL 2H 2019.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis Regains Compliance with Nasdaq Continued Listing Requirements
  2. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT
  4. Curis: 4Q Earnings Snapshot
  5. Curis Reports Fourth Quarter and Year-End 2018 Financial Results
  6. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  7. What's Driving The Rally In Microcap Biotech Curis?
  8. Biotech News: Why Curis Stock Is Soaring Today
  9. Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties
  10. Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million
  11. Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019
  12. Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference
  13. Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference
  14. Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
  15. First Mesothelioma Patient Dosed in CA-170 Study
  16. First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
  17. Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
  18. Top 3 Healthcare Penny Stocks for 2018
  19. Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results